We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

MorphoSys Announces Cross Licensing of Technologies with Lilly

MorphoSys Announces Cross Licensing of Technologies with Lilly

MorphoSys Announces Cross Licensing of Technologies with Lilly

MorphoSys Announces Cross Licensing of Technologies with Lilly

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Cross Licensing of Technologies with Lilly"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced a cross license agreement with Eli Lilly and Company on the use of certain recombinant protein technologies.

Under the agreement, MorphoSys receives a license under the Kauffman patent estate to generate and screen certain recombinant peptide and protein libraries and to commercialize any resulting products.

The agreement also provides Lilly access to the MorphoSys HuCAL GOLD® technology for Lilly's internal research & development programs.

For any therapeutic antibodies Lilly develops under the agreement, it will pay MorphoSys exclusive licensing fees, success fees, milestone payments and royalties on end products.

This agreement is part of a settlement to resolve patent litigation initiated by Applied Molecular Evolution (AME), a wholly owned subsidiary of Lilly, involving several U.S. patents of the Kauffman patent family.

The settlement agreement covers MorphoSys' and its partners' past, present and future use and commercialisation of all versions of its HuCAL® libraries, as well as its TRIM technology.

The agreement also gives Lilly access under agreed terms to Antibodies by Design, MorphoSys' business unit focusing on development of custom monoclonal antibodies for non-therapeutic purposes.

"We are very pleased to announce today's cross licensing agreement, which gives us greater flexibility in planning future generations of our proprietary HuCAL® antibody libraries," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

"We welcome Lilly's decision to join our stable of partners and look forward to working with them in a long-term partnership to develop innovative HuCAL(R) based antibody drugs."